{"custom_id":"syn7239560","result":{"type":"succeeded","message":{"id":"msg_01R4usMcc3J36kD5FN3o3rAR","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create a high-quality dataset metadata entry for the table in this project based on the provided information.\n\n```json\n[\n  {\n    \"title\": \"Compound Annotations from Evotec Drug Target Research\",\n    \"creator\": \"Tim James\",\n    \"contributor\": [\"Robert Allaway\", \"Evotec\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"compound structures\",\n      \"drug target\",\n      \"chemical properties\",\n      \"medicinal chemistry\",\n      \"small molecules\",\n      \"drug discovery\"\n    ],\n    \"dataType\": [\n      \"drugScreen\",\n      \"AggregatedData\"\n    ],\n    \"studyId\": \"syn7239560\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"CTF\"\n    ],\n    \"description\": \"This dataset contains compound structure data and annotations from Evotec's drug target research. It includes supplier-provided structures, unique structure properties computed from KNIME, and various compound annotations useful for drug discovery research. The data is presented in multiple formats including SDF files of chemical structures and CSV files of compound relationships.\",\n    \"alternateName\": \"Evotec NF1 Compound Library\",\n    \"datePublished\": 2017,\n    \"includedInDataCatalog\": \"https://www.synapse.org/DataCatalog:0\",\n    \"subject\": [\n      \"Medicinal chemistry\",\n      \"Drug discovery\",\n      \"Chemical informatics\",\n      \"Pharmaceutical research\"\n    ],\n    \"dataUseModifiers\": [\n      \"General Research Use\"\n    ]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5253,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":418}}}}
{"custom_id":"syn4939906","result":{"type":"succeeded","message":{"id":"msg_01DBAZ9xr2UDixQ12C39kam5","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata Curation\n\nBased on the provided information, I'll create high-quality dataset metadata for the three tables that conform to the JSON schema.\n\n```json\n[\n  {\n    \"title\": \"10x10 Combination Screens of pNF Cell Lines\",\n    \"creator\": \"Marc Ferrer\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"plexiform neurofibroma\",\n      \"drug combination screen\",\n      \"cell viability\",\n      \"synergy\",\n      \"drug efficacy\",\n      \"NF1\",\n      \"NTAP\"\n    ],\n    \"dataType\": [\n      \"drugCombinationScreen\"\n    ],\n    \"studyId\": \"syn4939906\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"description\": \"Results from 10x10 combinatorial drug screens performed on plexiform neurofibroma cell lines to identify synergistic drug combinations. This dataset represents the third-stage screening where top 72 compounds from 6x6 screens were tested in 10x10 combinations, focusing on 9 prioritized combinations for validation in mouse NF1-/- primary Schwann cells.\",\n    \"contributor\": [\n      \"Marc Ferrer\",\n      \"NCATS\"\n    ],\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"individualCount\": 4,\n    \"specimenCount\": 4,\n    \"manifestation\": [\n      \"Plexiform Neurofibroma\"\n    ],\n    \"datePublished\": 2017,\n    \"measurementTechnique\": \"cell viability assay\",\n    \"subject\": [\n      \"Drug combinations\", \n      \"Cancer drug screening\", \n      \"Cellular assays\"\n    ]\n  },\n  {\n    \"title\": \"6x6 Combination Screens of pNF Cell Lines\",\n    \"creator\": \"Marc Ferrer\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"plexiform neurofibroma\",\n      \"drug combination screen\",\n      \"cell viability\",\n      \"synergy\",\n      \"drug efficacy\",\n      \"NF1\",\n      \"NTAP\",\n      \"medium-throughput screening\"\n    ],\n    \"dataType\": [\n      \"drugCombinationScreen\"\n    ],\n    \"studyId\": \"syn4939906\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"description\": \"Results from 6x6 combinatorial drug screens performed on plexiform neurofibroma cell lines. This dataset represents the second-stage screening where top 40 compounds from the initial MIPE 4.0 single agent screens were tested in 780 different combinations to identify 72 unique combinations with optimal synergism profiles.\",\n    \"contributor\": [\n      \"Marc Ferrer\",\n      \"NCATS\"\n    ],\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"individualCount\": 6,\n    \"specimenCount\": 6,\n    \"manifestation\": [\n      \"Plexiform Neurofibroma\"\n    ],\n    \"datePublished\": 2017,\n    \"measurementTechnique\": \"cell viability assay\",\n    \"subject\": [\n      \"Drug combinations\", \n      \"Cancer drug screening\", \n      \"Cellular assays\"\n    ]\n  },\n  {\n    \"title\": \"Single Agent Screens of pNF Cell Lines\",\n    \"creator\": \"Marc Ferrer\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"plexiform neurofibroma\",\n      \"drug screen\",\n      \"cell viability\",\n      \"MIPE 4.0\",\n      \"high-throughput screening\",\n      \"NF1\",\n      \"NTAP\"\n    ],\n    \"dataType\": [\n      \"drugScreen\"\n    ],\n    \"studyId\": \"syn4939906\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"description\": \"Results from single agent screens of the MIPE 4.0 library of approximately 1912 small molecules against 9 different cell-lines (5 NF1 nullizygous, 1 carrier, 2 normal, and 1 control). This initial screening generated viability results for each cell line to identify approximately 40 top hits with the highest potency and efficacy.\",\n    \"contributor\": [\n      \"Marc Ferrer\",\n      \"NCATS\"\n    ],\n    \"species\": [\n      \"Homo sapiens\",\n      \"Mus musculus\"\n    ],\n    \"individualCount\": 11,\n    \"specimenCount\": 11,\n    \"manifestation\": [\n      \"Plexiform Neurofibroma\"\n    ],\n    \"datePublished\": 2017,\n    \"measurementTechnique\": \"cell viability assay\",\n    \"subject\": [\n      \"Drug screening\", \n      \"Cancer drug development\", \n      \"Cellular assays\"\n    ]\n  }\n]\n```\n\nThe metadata has been created according to the requirements with the following considerations:\n\n1. **Common elements across all datasets**:\n   - Creator is set to Marc Ferrer based on the project information\n   - AccessType is set to \"Controlled Access\" as these appear to be research data that may have restrictions\n   - License is set to \"UNKNOWN\" as no specific license information was provided\n   - Disease focus is set to \"Neurofibromatosis type 1\" based on the project description\n   - Funder is listed as \"NTAP\" as indicated in the project information\n   - Date published is set to 2017 based on the project dates (2014-2017)\n\n2. **Dataset-specific elements**:\n   - Each dataset has a unique description that captures its purpose within the overall screening workflow\n   - Keywords are tailored to each dataset while maintaining common terms relevant to the project\n   - Individual and specimen counts are set based on the provided information\n   - Species information is included as specified for each dataset\n   - The measurement technique is listed as \"cell viability assay\" based on the information provided\n   - Manifestation is set to \"Plexiform Neurofibroma\" as indicated in the tumor focus\n\nThese datasets represent a tiered drug screening approach, starting with single agent screens, followed by 6x6 combination screens of top hits, and finally 10x10 screens for the most promising combinations, all aimed at identifying effective drug treatments for plexiform neurofibromas."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6447,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1672}}}}
{"custom_id":"syn53185180","result":{"type":"succeeded","message":{"id":"msg_019rLC41GySHzwKDFcd4XsKr","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata JSON\n\n```json\n[\n  {\n    \"title\": \"MPNST Cell Line Colony Formation Assay Data\",\n    \"creator\": \"Raymond Mattingly\",\n    \"accessType\": \"Public Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"colony formation\", \"cell viability\", \"NF1\", \"cell line\", \"lovastatin\", \"farnesyltransferase inhibitor\"],\n    \"dataType\": [\"cellularPhysiology\"],\n    \"studyId\": \"syn53185180\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\", \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"funder\": [\"GFF\"],\n    \"description\": \"Colony formation assay data from NF1-associated MPNST cell lines testing the effects of combination treatment with statins and prodrug farnesyltransferase inhibitors. The dataset includes results from multiple MPNST cell lines showing cellular response to the targeted RAS pathway interventions.\",\n    \"contributor\": [\"Raymond Mattingly\", \"Robert Allaway\"],\n    \"measurementTechnique\": \"cell proliferation\",\n    \"species\": [\"Homo sapiens\", \"Rattus norvegicus\"],\n    \"subject\": [\"Neurofibromatosis type 1\", \"Cancer research\", \"Drug discovery\", \"Cell proliferation\"]\n  }\n]\n```\n\nI've created a metadata record for the colony forming assay dataset based on the available information. Here's what I included:\n\n1. **Basic Required Fields**:\n   - Title: Descriptive title indicating the assay type and focus\n   - Creator: Used the PI (Raymond Mattingly)\n   - Access Type: Set as Public Access since no restrictions were indicated\n   - License: UNKNOWN as specific license terms were not provided\n   - Keywords: Relevant terms related to the study focus\n   - Data Type: cellularPhysiology as this involves cell growth/proliferation measurement\n   - Study ID: Included the project ID\n   - Disease Focus: Included both NF1 and MPNST based on the project description\n   - Funder: GFF as indicated in the project information\n\n2. **Additional Context**:\n   - Description: Summarized the purpose and content of the dataset\n   - Contributor: Included both the PI and Robert Allaway who was listed as creating data\n   - Measurement Technique: Listed as cell proliferation since colony formation assays measure cell growth\n   - Species: Included both human and rat based on the filenames (ST88-14 and S462TY are human MPNST lines, and \"Schwann_rat\" indicates rat cells)\n   - Subject: Added relevant Library of Congress subject headings\n\nThe data appears to contain colony formation assay results from experiments testing the combination of statins and farnesyltransferase inhibitors on MPNST cell lines, aligning with the project's goal of developing a combinatorial approach to block RAS activation in NF1-associated tumors."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5417,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":709}}}}
{"custom_id":"syn20608511","result":{"type":"succeeded","message":{"id":"msg_01Kt33ENRxd3MtZ1SXiDqy2b","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata\n\nI'll create the dataset metadata according to the JSON schema based on the provided information about the Whole Body MRI of NF Patients project.\n\n```json\n[\n  {\n    \"title\": \"Whole Body MRI of NF Patients\",\n    \"creator\": \"Dr. Wenli Cai and Dr. Gordon Harris\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole-body MRI\", \"NF1\", \"NF2\", \"schwannomatosis\", \"STIR\", \"T1\", \"tumor burden\", \"imaging\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn20608511\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\", \"NF2-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"This dataset contains whole-body MRI imaging data from 48 patients with NF1, NF2, and schwannomatosis. It includes two image modalities (STIR and T1) with corresponding clinical metadata on tumor burden, type, and location. The data is intended for developing improved tumor segmentation algorithms and identifying MRI features to diagnose specific tumor types or predict disease progression.\",\n    \"contributor\": [\"Dr. Wenli Cai\", \"Dr. Gordon Harris\", \"Robert Allaway\", \"Jineta Banerjee\"],\n    \"conditionsOfAccess\": \"Users must request access to the data by following the instructions in 'Accessing the Data' section of the project.\",\n    \"dataUseModifiers\": [\"General Research Use\", \"Health or Medical or Biomedical Research\"],\n    \"individualCount\": 48,\n    \"specimenCount\": 48,\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"conventional MRI\",\n    \"alternateName\": \"MGH WBMRI NF Dataset\",\n    \"subject\": [\"Neurofibromatosis\", \"Whole-body magnetic resonance imaging\", \"Tumor burden\", \"Medical imaging\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\", \"Schwannoma\"]\n  }\n]\n```\n\nThis metadata accurately captures the information from the provided project summary, including:\n\n1. Basic information about the dataset (title, creator, access type)\n2. Disease focus covering the three mentioned conditions (NF1, NF2, schwannomatosis)\n3. Details about the data contents (MRI imaging with STIR and T1 modalities)\n4. Information about the study participants (48 patients with various NF conditions)\n5. Appropriate keywords and subject classifications\n6. Clear description of the dataset purpose and content\n7. Access conditions reflecting the controlled nature of the data\n8. The appropriate measurement technique (conventional MRI)\n9. Contributors including both the PIs and other data contributors\n\nAll required fields are included according to the schema, and optional fields are populated where information was available."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5617,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":716}}}}
{"custom_id":"syn51133914","result":{"type":"succeeded","message":{"id":"msg_01QnMu8L9EKzHaa4x4E8LbRC","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the two tables in this project based on the information provided.\n\n```json\n[\n  {\n    \"title\": \"Histopathology of Human Plexiform Neurofibroma, ANNUBP and MPNST Specimens\",\n    \"creator\": \"Steven Rhodes\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"histopathology\",\n      \"neurofibromatosis\",\n      \"plexiform neurofibroma\",\n      \"MPNST\",\n      \"ANNUBP\",\n      \"brightfield microscopy\",\n      \"NF1\"\n    ],\n    \"dataType\": [\n      \"image\"\n    ],\n    \"studyId\": \"syn51133914\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NIH-NCI\"\n    ],\n    \"contributor\": [\n      \"Steven Rhodes\",\n      \"Andrew Horvai\",\n      \"Elliot Stieglitz\"\n    ],\n    \"description\": \"This dataset contains histopathological images of human plexiform neurofibroma, aneurysmal bone cyst (ANNUBP), and malignant peripheral nerve sheath tumor (MPNST) specimens from 61 individuals diagnosed with Neurofibromatosis type 1. The data includes brightfield microscopy images in SVS format along with supporting XML, PDF, and Excel files.\",\n    \"individualCount\": 61,\n    \"specimenCount\": 61,\n    \"manifestation\": [\n      \"Plexiform Neurofibroma\",\n      \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\",\n      \"Aneurysmal Bone Cyst (ANNUBP)\"\n    ],\n    \"measurementTechnique\": \"brightfield microscopy\",\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"subject\": [\n      \"Histopathology\",\n      \"Neuro-oncology\",\n      \"Tumor imaging\"\n    ],\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ]\n  },\n  {\n    \"title\": \"Van Andel Kinome Profiling of NF1 Samples\",\n    \"creator\": \"Steven Angus\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"kinomics\",\n      \"MIB/MS\",\n      \"neurofibromatosis\",\n      \"proteomics\",\n      \"NF1\",\n      \"kinase activity\"\n    ],\n    \"dataType\": [\n      \"kinomics\"\n    ],\n    \"studyId\": \"syn51133914\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NIH-NCI\"\n    ],\n    \"contributor\": [\n      \"Steven Angus\",\n      \"Sara Gosline\"\n    ],\n    \"description\": \"This dataset contains kinome profiling data generated through MIB/MS (Multiplexed Inhibitor Beads with Mass Spectrometry) from 16 individuals with Neurofibromatosis type 1. The data is presented in Excel spreadsheets and CSV files containing log2 LFQ values and other kinome metrics.\",\n    \"individualCount\": 16,\n    \"measurementTechnique\": \"MIB/MS\",\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"subject\": [\n      \"Kinome profiling\",\n      \"Proteomics\",\n      \"Molecular oncology\"\n    ],\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6024,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":952}}}}
{"custom_id":"syn22268639","result":{"type":"succeeded","message":{"id":"msg_016Pk8Z26ryfZdAEyYENH1LB","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata Curation\n\nI'll create high-quality metadata for this dataset based on the provided information.\n\n```json\n[\n  {\n    \"title\": \"P2RY14 Signaling in Neurofibromatosis Type 1\",\n    \"creator\": \"Jennifer Patritti Cram\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"P2RY14\", \n      \"purinergic signaling\", \n      \"neurofibromatosis\", \n      \"Schwann cells\", \n      \"tumor initiation\", \n      \"western blot\", \n      \"neurofibroma\"\n    ],\n    \"dataType\": [\n      \"immunoassay\"\n    ],\n    \"studyId\": \"syn22268639\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"CTF\"\n    ],\n    \"description\": \"This dataset contains western blot immunoassay data investigating the role of purinergic receptor P2RY14 in tumor formation in neurofibromatosis type 1 (NF1). The study explores signaling pathways like ERK and AKT in relation to P2RY14 expression in both human and mouse neurofibroma models, supporting research on tumor formation mechanisms and potential therapeutic targets.\",\n    \"contributor\": [\n      \"Jennifer Patritti Cram\",\n      \"Cincinnati Medical Center\"\n    ],\n    \"species\": [\n      \"Homo sapiens\", \n      \"Mus musculus (humanized)\"\n    ],\n    \"manifestation\": [\n      \"Plexiform Neurofibroma\"\n    ],\n    \"measurementTechnique\": \"western blot\",\n    \"subject\": [\n      \"Neurofibromatosis\",\n      \"Signal transduction\",\n      \"Tumor biology\",\n      \"Purinergic receptors\"\n    ],\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ]\n  }\n]\n```\n\nThis metadata follows the required JSON schema and accurately represents the dataset. I've included:\n\n1. A clear, descriptive title that includes the main subject (P2RY14) and disease focus (NF1)\n2. The creator as identified in the abstract\n3. Controlled access type (standard for human patient data)\n4. Appropriate keywords covering the main concepts in the research\n5. Accurate disease focus of Neurofibromatosis type 1\n6. CTF as the funder\n7. A concise description summarizing the content and purpose of the dataset\n8. Both species identified in the table summary\n9. Plexiform Neurofibroma as the manifestation (inferred from the abstract)\n10. Western blot as the measurement technique\n11. Relevant subject tags for improved discoverability\n12. Appropriate data use modifier\n\nThe description provides context about the scientific purpose while keeping under the 500 character limit."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6640,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":721}}}}
{"custom_id":"syn32128792","result":{"type":"succeeded","message":{"id":"msg_0151yTnkGHixh7Dn3Hkibj2L","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these three tables based on the provided information and schema.\n\n```json\n[\n  {\n    \"title\": \"NFRI GeM Consortium RNA-Seq Raw Data (EGA)\",\n    \"creator\": \"David Miller\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"RNA-Seq\", \n      \"MPNST\", \n      \"Malignant Peripheral Nerve Sheath Tumor\", \n      \"Neurofibromatosis type 1\",\n      \"Genomics\",\n      \"Sequencing\",\n      \"Raw data\"\n    ],\n    \"dataType\": [\n      \"geneExpression\",\n      \"raw counts\"\n    ],\n    \"studyId\": \"syn32128792\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"alternateName\": \"NFRI Genomics of MPNST Consortium RNA-Seq Data\",\n    \"conditionsOfAccess\": \"This dataset requires EGA approval. Data must be accessed directly through EGA (EGAD00001008608).\",\n    \"contributor\": [\n      \"Katherine Piculell\",\n      \"Boston Children's Hospital\",\n      \"NFRI GeM Consortium\"\n    ],\n    \"description\": \"This dataset contains RNA-seq raw data (FASTQ files) from the NFRI Genomics of MPNST (GeM) Consortium study. It includes samples from 79 individuals with 139 specimens, focusing on Malignant Peripheral Nerve Sheath Tumors (MPNSTs) in the context of Neurofibromatosis type 1. Data access requires approval through the European Genome-phenome Archive (EGA).\",\n    \"individualCount\": 79,\n    \"manifestation\": [\n      \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"\n    ],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"specimenCount\": 139,\n    \"subject\": [\n      \"Genomics\",\n      \"Neurofibromatosis\",\n      \"Cancer genomics\",\n      \"Sarcoma\"\n    ],\n    \"visualizeDataOn\": [\n      \"https://ega-archive.org/datasets/EGAD00001008608\"\n    ]\n  },\n  {\n    \"title\": \"NFRI GeM Consortium RNA-Seq Processed Gene Quantification Data (EGA)\",\n    \"creator\": \"David Miller\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"RNA-Seq\", \n      \"MPNST\", \n      \"Malignant Peripheral Nerve Sheath Tumor\", \n      \"Neurofibromatosis type 1\",\n      \"Gene quantification\",\n      \"Processed data\"\n    ],\n    \"dataType\": [\n      \"geneExpression\"\n    ],\n    \"studyId\": \"syn32128792\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"alternateName\": \"NFRI GeM Consortium Gene-Level Transcript Quantification Data\",\n    \"conditionsOfAccess\": \"This dataset requires EGA approval. Data must be accessed directly through EGA (EGAD00001008608).\",\n    \"contributor\": [\n      \"Katherine Piculell\",\n      \"Boston Children's Hospital\",\n      \"NFRI GeM Consortium\"\n    ],\n    \"description\": \"This dataset contains processed RNA-seq data in the form of gene-level quantification files (quant.genes.sf) from the NFRI Genomics of MPNST (GeM) Consortium study. It includes processed data from 79 individuals with 139 specimens, focusing on MPNSTs in the context of Neurofibromatosis type 1. Data access requires approval through EGA.\",\n    \"individualCount\": 79,\n    \"manifestation\": [\n      \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"\n    ],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"specimenCount\": 139,\n    \"subject\": [\n      \"Genomics\",\n      \"Neurofibromatosis\",\n      \"Cancer genomics\",\n      \"Transcriptomics\",\n      \"Sarcoma\"\n    ],\n    \"visualizeDataOn\": [\n      \"https://ega-archive.org/datasets/EGAD00001008608\"\n    ]\n  },\n  {\n    \"title\": \"NFRI GeM Consortium RNA-Seq Processed Transcript Quantification Data (EGA)\",\n    \"creator\": \"Robert Allaway\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"RNA-Seq\", \n      \"MPNST\", \n      \"Malignant Peripheral Nerve Sheath Tumor\", \n      \"Neurofibromatosis type 1\",\n      \"Transcript quantification\",\n      \"Processed data\"\n    ],\n    \"dataType\": [\n      \"geneExpression\"\n    ],\n    \"studyId\": \"syn32128792\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"alternateName\": \"NFRI GeM Consortium Transcript-Level Quantification Data\",\n    \"conditionsOfAccess\": \"This dataset requires EGA approval. Data must be accessed directly through EGA (EGAD00001008608).\",\n    \"contributor\": [\n      \"Katherine Piculell\",\n      \"David Miller\",\n      \"Boston Children's Hospital\",\n      \"NFRI GeM Consortium\"\n    ],\n    \"description\": \"This dataset contains processed RNA-seq data in the form of transcript-level quantification files (quant.sf) from the NFRI Genomics of MPNST (GeM) Consortium study. It includes processed data from 79 individuals with 139 specimens, focusing on MPNSTs in the context of Neurofibromatosis type 1. Data access requires approval through EGA.\",\n    \"individualCount\": 79,\n    \"manifestation\": [\n      \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"\n    ],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"specimenCount\": 139,\n    \"subject\": [\n      \"Genomics\",\n      \"Neurofibromatosis\",\n      \"Cancer genomics\",\n      \"Transcriptomics\",\n      \"Sarcoma\"\n    ],\n    \"visualizeDataOn\": [\n      \"https://ega-archive.org/datasets/EGAD00001008608\"\n    ]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5862,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1780}}}}
{"custom_id":"syn22268689","result":{"type":"succeeded","message":{"id":"msg_01PBsdTznFp9h5kFAJFKzNFW","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the two tables based on the provided information. Let me analyze the data and generate JSON that conforms to the specified schema.\n\n```json\n[\n  {\n    \"title\": \"LZTR1 Mutation Proteomics Dataset\",\n    \"creator\": \"Aram Ko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"LZTR1\",\n      \"proteomics\",\n      \"schwannomatosis\",\n      \"mass spectrometry\",\n      \"TMT quantitation\",\n      \"ubiquitination\",\n      \"EGFR\",\n      \"AXL\"\n    ],\n    \"dataType\": [\n      \"proteomics\"\n    ],\n    \"studyId\": \"syn22268689\",\n    \"diseaseFocus\": [\n      \"LZTR1-related schwannomatosis\"\n    ],\n    \"funder\": [\n      \"CTF\"\n    ],\n    \"alternateName\": \"LZTR1 Substrate Identification Proteomics\",\n    \"description\": \"Mass spectrometry and TMT quantitation data identifying and characterizing LZTR1 substrates in human and mouse cells. This dataset supports findings that LZTR1 mutation mediates oncogenesis through stabilization of EGFR and AXL through the loss of ubiquitin-mediated protein degradation.\",\n    \"contributor\": [\n      \"Aram Ko\",\n      \"James Moon\"\n    ],\n    \"datePublished\": 2023,\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ],\n    \"includedInDataCatalog\": \"https://www.synapse.org/DataCatalog:0\",\n    \"measurementTechnique\": \"mass spectrometry\",\n    \"species\": [\n      \"Homo sapiens\",\n      \"Mus musculus\"\n    ],\n    \"specimenCount\": 1,\n    \"subject\": [\n      \"Ubiquitin-Proteasome System\",\n      \"Proteomics\",\n      \"Schwannomatosis\",\n      \"Tumor Suppressor Proteins\"\n    ]\n  },\n  {\n    \"title\": \"LZTR1 In Vitro Viability Assay Dataset\",\n    \"creator\": \"Aram Ko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"LZTR1\",\n      \"drug screen\",\n      \"viability assay\",\n      \"schwannomatosis\",\n      \"cell viability\",\n      \"drug combinations\"\n    ],\n    \"dataType\": [\n      \"drugCombinationScreen\"\n    ],\n    \"studyId\": \"syn22268689\",\n    \"diseaseFocus\": [\n      \"LZTR1-related schwannomatosis\"\n    ],\n    \"funder\": [\n      \"CTF\"\n    ],\n    \"alternateName\": \"LZTR1 Drug Sensitivity Screening\",\n    \"description\": \"Cell viability assay data assessing the sensitivity of mouse cells with LZTR1 alterations to various drug treatments and combinations. This dataset supports research into potential therapeutic approaches for LZTR1-driven schwannomatosis.\",\n    \"contributor\": [\n      \"Aram Ko\",\n      \"James Moon\"\n    ],\n    \"datePublished\": 2023,\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ],\n    \"includedInDataCatalog\": \"https://www.synapse.org/DataCatalog:0\",\n    \"measurementTechnique\": \"cell viability assay\",\n    \"species\": [\n      \"Mus musculus\"\n    ],\n    \"subject\": [\n      \"Drug Screening\",\n      \"Cell Viability\",\n      \"Schwannomatosis\",\n      \"Preclinical Studies\"\n    ]\n  }\n]\n```\n\nThis metadata provides rich, accurate descriptions for both datasets from the LZTR1 mutation study. For each dataset, I've included:\n\n1. Complete required fields (title, creator, accessType, license, keywords, dataType, studyId, diseaseFocus, funder)\n2. Descriptive titles that clearly indicate the nature of each dataset\n3. Specific keywords relevant to each dataset type\n4. Clear descriptions that explain the purpose and significance of the data\n5. Appropriate measurement techniques from the allowed enumeration values\n6. Properly formatted species information\n7. Relevant subjects for improved discoverability\n8. Accurate contributor information\n9. Additional contextual information where available\n\nThe metadata follows the schema requirements precisely and provides valuable context about these important datasets for researchers studying LZTR1-related schwannomatosis."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6406,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1153}}}}
{"custom_id":"syn11374345","result":{"type":"succeeded","message":{"id":"msg_01V3QGe4XQdKZB8MPJKsd5Nw","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata Curation for Project syn11374345\n\nBased on the provided information, I've created metadata for all four tables in the project following the schema requirements.\n\n```json\n[\n  {\n    \"title\": \"12 Month NF1 Sensory Neuron Impact on Schwann Cell Growth Data\",\n    \"creator\": \"Corina Anastasaki\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"iPSCs\", \"Schwann cells\", \"sensory neurons\", \"NF1\", \"immunofluorescence\", \"real-time PCR\"],\n    \"dataType\": [\"image\", \"geneExpression\"],\n    \"studyId\": \"syn11374345\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains results from 12-month deliverables, including immunofluorescence images and real-time PCR data studying the impact of NF1 germline mutations in sensory neurons on human Schwann cell growth.\",\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"contributor\": [\"Corina Anastasaki\", \"David H. Gutmann\"],\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"datePublished\": 2019\n  },\n  {\n    \"title\": \"18 Month NF1 Sensory Neuron Characterization Data\",\n    \"creator\": \"Corina Anastasaki\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"iPSCs\", \"sensory neurons\", \"NF1\", \"immunocytochemistry\", \"gene expression\", \"BRN3A\", \"NF200\", \"TRKA\"],\n    \"dataType\": [\"image\", \"geneExpression\"],\n    \"studyId\": \"syn11374345\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains 18-month deliverables focusing on the characterization of sensory neurons derived from human iPSCs with NF1 mutations, including immunocytochemistry of neural markers and qPCR expression data.\",\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"Corina Anastasaki\", \"Christina Parry\", \"David H. Gutmann\"],\n    \"measurementTechnique\": \"immunocytochemistry\",\n    \"datePublished\": 2020\n  },\n  {\n    \"title\": \"30 Month NF1 Sensory Neuron Electrophysiology and Schwann Cell Proliferation Data\",\n    \"creator\": \"Corina Anastasaki\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"iPSCs\", \"sensory neurons\", \"Schwann cells\", \"NF1\", \"electrophysiology\", \"cell proliferation\", \"MEA\", \"DRG\"],\n    \"dataType\": [\"electrophysiology\", \"raw counts\"],\n    \"studyId\": \"syn11374345\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains 30-month deliverables including multi-electrode array recordings of sensory neurons and proliferation assays of Schwann cells in response to NF1-mutant sensory neurons, comparing human and mouse models.\",\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"contributor\": [\"Corina Anastasaki\", \"David H. Gutmann\"],\n    \"measurementTechnique\": \"local field potential recording\",\n    \"datePublished\": 2020\n  },\n  {\n    \"title\": \"6 Month NF1 Schwann Cell Characterization Data\",\n    \"creator\": \"Corina Anastasaki\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"iPSCs\", \"Schwann cells\", \"NF1\", \"immunocytochemistry\", \"western blot\", \"qPCR\", \"Schwann cell markers\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374345\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains 6-month deliverables focusing on the characterization of Schwann cells derived from human iPSCs with NF1 mutations, including immunocytochemistry of Schwann cell markers and protein expression analysis.\",\n    \"species\": [\"Homo sapiens\"],\n    \"specimenCount\": 2,\n    \"contributor\": [\"Corina Anastasaki\", \"David H. Gutmann\"],\n    \"measurementTechnique\": \"immunocytochemistry\",\n    \"datePublished\": 2019\n  }\n]\n```\n\nI've created detailed metadata for each table that:\n\n1. Uses appropriate titles that reflect the content and timepoint of each dataset\n2. Includes the creator (Corina Anastasaki) who created the data\n3. Sets access type as \"Controlled Access\" based on NTAP data policies\n4. Adds relevant keywords based on the research topic and methods\n5. Accurately categorizes data types according to the schema's options\n6. Includes the study ID linking to the parent project\n7. Specifies Neurofibromatosis type 1 as the disease focus\n8. Lists NTAP as the funder\n9. Provides concise descriptions that summarize each dataset's content\n10. Includes species information where available\n11. Lists contributors and appropriate measurement techniques\n12. Adds specimen counts when available\n13. Estimates datePublished based on the deliverable timepoints\n\nThe metadata provides comprehensive and structured information about these datasets while conforming to the required JSON schema."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6489,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1441}}}}
{"custom_id":"syn9727752","result":{"type":"succeeded","message":{"id":"msg_014LtCYDHWy8pN19JRLAP2Lp","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each table in the project according to the JSON schema provided. Based on the information available, I'll create accurate and helpful metadata entries.\n\n```json\n[\n  {\n    \"title\": \"Deep Variant Tumor Calls\",\n    \"creator\": \"CTF Synodos Schwannomatosis Consortium\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"variant calls\", \"tumor\", \"genomics\"],\n    \"dataType\": [\"genomicVariants\", \"SomaticVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Deep variant calls from tumor samples from the Synodos for Schwannomatosis project, which aims to identify disease-driving alterations through genomic analysis.\",\n    \"subject\": [\"Schwannomatosis\", \"Genomic sequencing\", \"Cancer genetics\"]\n  },\n  {\n    \"title\": \"Methylation Array Data from Schwannomatosis Tumors\",\n    \"creator\": \"Sheila Mansouri\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"methylation\", \"epigenomics\", \"schwannomatosis\", \"schwannoma\", \"tumor\", \"array\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Methylation array data (.idat files) from 91 schwannoma specimens from 45 individuals with schwannomatosis, generated to establish the epigenomic landscape of schwannomatosis and identify disease-driving alterations.\",\n    \"individualCount\": 45,\n    \"specimenCount\": 91,\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"methylation array\",\n    \"subject\": [\"Schwannomatosis\", \"Epigenetics\", \"DNA methylation\"]\n  },\n  {\n    \"title\": \"RNA-seq Data from Schwannomatosis Tumors\",\n    \"creator\": \"Robert Allaway\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"transcriptomics\", \"schwannomatosis\", \"schwannoma\", \"gene expression\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"RNA sequencing data (fastq files) from 24 schwannoma specimens from 14 individuals with schwannomatosis, generated to characterize gene expression patterns and identify potential therapeutic targets.\",\n    \"individualCount\": 14,\n    \"specimenCount\": 24,\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"subject\": [\"Schwannomatosis\", \"Gene expression\", \"Transcriptomics\"]\n  },\n  {\n    \"title\": \"SWNTS Processing 2020-05-13\",\n    \"creator\": \"CTF Synodos Schwannomatosis Consortium\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"data processing\", \"bioinformatics\"],\n    \"dataType\": [\"AggregatedData\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Processed data from the Synodos for Schwannomatosis project, dated May 13, 2020, containing processed outputs from various analyses performed on schwannomatosis samples.\"\n  },\n  {\n    \"title\": \"Schwannomatosis RNA-seq Raw Data (NF-OSI Merged fastq)\",\n    \"creator\": \"CTF Synodos Schwannomatosis Consortium\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"transcriptomics\", \"schwannomatosis\", \"merged fastq\", \"raw data\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Merged fastq files from RNA-seq data of 24 schwannoma specimens from 14 individuals with schwannomatosis, processed by NF-OSI to combine multiple sequencing lanes.\",\n    \"individualCount\": 14,\n    \"specimenCount\": 24,\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"series\": \"NF-OSI Processed Data\",\n    \"yearProcessed\": 2020\n  },\n  {\n    \"title\": \"Schwannomatosis RNA-seq Raw Data (Unmerged, Original fastq)\",\n    \"creator\": \"CTF Synodos Schwannomatosis Consortium\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"transcriptomics\", \"schwannomatosis\", \"raw data\", \"fastq\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Original, unmerged fastq files from RNA-seq data of schwannoma specimens from individuals with schwannomatosis, representing the raw output from the sequencing facility.\"\n  },\n  {\n    \"title\": \"Schwannomatosis RNA-seq Salmon Quantification Files\",\n    \"creator\": \"CTF Synodos Schwannomatosis Consortium\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"transcriptomics\", \"schwannomatosis\", \"salmon\", \"quantification\", \"gene expression\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Transcript and gene-level quantification files (quant.sf and quant.genes.sf) generated using Salmon from RNA-seq data of 22 schwannoma specimens from 14 individuals with schwannomatosis.\",\n    \"individualCount\": 14,\n    \"specimenCount\": 22,\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"series\": \"NF-OSI Processed Data\"\n  },\n  {\n    \"title\": \"Somatic Mutations\",\n    \"creator\": \"CTF Synodos Schwannomatosis Consortium\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"somatic mutations\", \"schwannomatosis\", \"vcf\", \"variant calling\", \"strelka\"],\n    \"dataType\": [\"SomaticVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Somatic mutation calls (VCF files) from tumor-normal pairs from patients with schwannomatosis, generated using the Strelka variant caller.\",\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"Somatic Variants - Strelka - WES\",\n    \"creator\": \"Sasha Scott\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"somatic variants\", \"strelka\", \"whole exome sequencing\", \"schwannomatosis\", \"vcf\"],\n    \"dataType\": [\"SomaticVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Somatic variant calls (SNVs and indels) from whole exome sequencing data of 40 schwannoma specimens from 22 individuals with schwannomatosis, generated using the Strelka variant caller.\",\n    \"individualCount\": 22,\n    \"specimenCount\": 40,\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"whole exome sequencing\",\n    \"subject\": [\"Schwannomatosis\", \"Cancer genomics\", \"Somatic mutations\"]\n  },\n  {\n    \"title\": \"Whole Genome Sequencing Data from Schwannomatosis Patients\",\n    \"creator\": \"Robert Allaway\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole genome sequencing\", \"schwannomatosis\", \"schwannoma\", \"genomics\", \"fastq\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Whole genome sequencing data (fastq files) from 18 specimens (tumor and matched normal) from 8 individuals with schwannomatosis, generated to identify genomic alterations and driver mutations.\",\n    \"individualCount\": 8,\n    \"specimenCount\": 18,\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"whole genome sequencing\",\n    \"subject\": [\"Schwannomatosis\", \"Genomics\", \"Cancer genetics\"]\n  },\n  {\n    \"title\": \"Whole Exome Sequencing Data from Schwannomatosis Patients\",\n    \"creator\": \"Fulvio D'Angelo\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole exome sequencing\", \"schwannomatosis\", \"schwannoma\", \"genomics\", \"fastq\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Whole exome sequencing data (fastq files) from 91 specimens (tumor and matched normal) from 38 individuals with schwannomatosis, generated to identify exonic variants and driver mutations.\",\n    \"individualCount\": 38,\n    \"specimenCount\": 91,\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"whole exome sequencing\",\n    \"subject\": [\"Schwannomatosis\", \"Exome sequencing\", \"Cancer genetics\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7694,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2973}}}}
{"custom_id":"syn4939916","result":{"type":"succeeded","message":{"id":"msg_01WzJcUqjcYFjZsHZqdKoa8i","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the table based on the provided information. Here's my curated metadata in JSON format:\n\n```json\n[\n  {\n    \"title\": \"Screening of Plexiform Neurofibroma Models in 96-well Format\",\n    \"creator\": \"Raymond Mattingly\",\n    \"alternateName\": \"Cell Viability Assays of Plexiform Neurofibroma Models in 2D and 3D Culture\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"plexiform neurofibroma\",\n      \"drug screening\",\n      \"cell viability\",\n      \"2D culture\",\n      \"3D culture\",\n      \"96-well format\",\n      \"drug sensitivity\",\n      \"secondary screening\"\n    ],\n    \"dataType\": [\n      \"drugScreen\",\n      \"cellularPhysiology\"\n    ],\n    \"dataUseModifiers\": [\n      \"General Research Use\"\n    ],\n    \"description\": \"This dataset contains results from comparative drug sensitivity testing of plexiform neurofibroma models in both 2D and 3D culture formats using 96-well plates. The experiments assess cell viability following drug treatment, with the hypothesis that 3D culture models may better predict clinical drug effectiveness than traditional 2D cultures.\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"includedInDataCatalog\": \"https://www.synapse.org/DataCatalog:0\",\n    \"manifestation\": [\n      \"Plexiform Neurofibroma\"\n    ],\n    \"measurementTechnique\": \"cell viability assay\",\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"studyId\": \"syn4939916\",\n    \"subject\": [\n      \"Drug screening\",\n      \"Cell culture models\",\n      \"Neurofibroma\",\n      \"Translational models\"\n    ],\n    \"contributor\": [\n      \"Raymond Mattingly\",\n      \"Markiesha Baines\"\n    ]\n  }\n]\n```\n\nThis metadata captures the essential information about the dataset while conforming to the required JSON schema. I've included all the required fields and several optional ones that are relevant to this dataset. The description provides a concise overview of the dataset's content and purpose, while keywords and subjects help with discoverability."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5832,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":593}}}}
{"custom_id":"syn11374333","result":{"type":"succeeded","message":{"id":"msg_01UdbE14LFdJF9KciotRjs5F","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each of the 5 tables in this NF1 research project, following the JSON schema provided.\n\n```json\n[\n  {\n    \"title\": \"Cutaneous Neurofibroma 12 Month Deliverables\",\n    \"creator\": \"Lu Q. Le\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunofluorescence\", \"cutaneous neurofibroma\", \"NF1\", \"tumor microenvironment\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Lu Q. Le\", \"Robert Allaway\"],\n    \"description\": \"Microscopy images collected at the 12-month milestone of the cutaneous neurofibroma (cNF) research project. Data includes immunofluorescence images examining the cellular and molecular characteristics of cNF development to better understand the cell of origin and pathogenesis.\",\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"specimenCount\": 1,\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"subject\": [\"Neurofibromatosis type 1\", \"Cutaneous neurofibroma\", \"Tumor development\", \"Cellular imaging\"]\n  },\n  {\n    \"title\": \"Cutaneous Neurofibroma 18 Month Deliverables\",\n    \"creator\": \"Lu Q. Le\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunofluorescence\", \"cutaneous neurofibroma\", \"NF1\", \"tumor development\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Lu Q. Le\"],\n    \"description\": \"This dataset contains immunofluorescence microscopy images collected at the 18-month research milestone of the cutaneous neurofibroma project. The images represent continued investigation into cNF cellular origin and development mechanisms.\",\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"subject\": [\"Neurofibromatosis type 1\", \"Cutaneous neurofibroma\", \"Cellular imaging\", \"Tumor microenvironment\"]\n  },\n  {\n    \"title\": \"Cutaneous Neurofibroma 24 Month Deliverables\",\n    \"creator\": \"Lu Q. Le\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunofluorescence\", \"immunohistochemistry\", \"qPCR\", \"western blot\", \"cutaneous neurofibroma\", \"NF1\", \"gene expression\"],\n    \"dataType\": [\"image\", \"geneExpression\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Lu Q. Le\"],\n    \"description\": \"Multi-modal research data from the 24-month milestone of the cutaneous neurofibroma project. Includes microscopy images (immunofluorescence, brightfield, immunohistochemistry) and molecular analyses (qPCR, western blot) examining various neurofibroma types with focus on cNF pathogenesis.\",\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\"],\n    \"subject\": [\"Neurofibromatosis type 1\", \"Cutaneous neurofibroma\", \"Plexiform neurofibroma\", \"Gene expression\", \"Tumor development\"]\n  },\n  {\n    \"title\": \"Cutaneous Neurofibroma 36 Month Deliverables\",\n    \"creator\": \"Lu Q. Le\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunohistochemistry\", \"immunofluorescence\", \"microscopy\", \"cell counting\", \"whole exome sequencing\", \"reporter gene assay\", \"neurofibroma\"],\n    \"dataType\": [\"image\", \"geneExpression\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Lu Q. Le\", \"Renee McKay\"],\n    \"description\": \"Final milestone data from the cutaneous neurofibroma research project. Contains comprehensive imaging, cell quantification, and genomic analyses examining both human and mouse samples. Includes comparative analyses between cutaneous and plexiform neurofibromas focusing on NF1 heterozygous and null states.\",\n    \"measurementTechnique\": \"immunohistochemistry\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"subject\": [\"Neurofibromatosis type 1\", \"Cutaneous neurofibroma\", \"Plexiform neurofibroma\", \"Mouse models\", \"Schwann cell precursors\", \"Genomic analysis\"]\n  },\n  {\n    \"title\": \"Cutaneous Neurofibroma 6 Month Deliverables\",\n    \"creator\": \"Lu Q. Le\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunofluorescence\", \"NF1\", \"cutaneous neurofibroma\", \"initial data\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Lu Q. Le\", \"Robert Allaway\"],\n    \"description\": \"Initial dataset from the 6-month milestone of the cutaneous neurofibroma research project. Contains immunofluorescence microscopy images related to early investigations of the cNF cellular origin and molecular characterization.\",\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"specimenCount\": 1,\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"subject\": [\"Neurofibromatosis type 1\", \"Cutaneous neurofibroma\", \"Cellular imaging\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6720,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1620}}}}
{"custom_id":"syn21650493","result":{"type":"succeeded","message":{"id":"msg_015LRuhMF5pgcQ2db4qZpAxj","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create dataset metadata for all 18 tables in this project, following the JSON schema provided.\n\n```json\n[\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"AAV Ascl1 v YapS5A EdU\",\n    \"description\": \"This dataset contains quantitative measurements of EdU-positive cells from immunofluorescence studies comparing AAV-mediated expression of Ascl1 versus YapS5A in mouse retina.\",\n    \"dataType\": [\"immunoassay\", \"raw counts\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"Ascl1\", \"YapS5A\", \"EdU labeling\", \"proliferation\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Mus musculus\"],\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"AAV Ascl1 v YapS5A EdU image\",\n    \"description\": \"Immunofluorescence microscopy images comparing AAV-mediated expression of Ascl1 versus YapS5A in mouse retina, with EdU labeling to identify proliferating cells.\",\n    \"dataType\": [\"immunoassay\", \"image\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"Ascl1\", \"YapS5A\", \"EdU labeling\", \"immunofluorescence\", \"microscopy\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Mus musculus\"],\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"ATACseq Ascl1a lin28a OE v control uninj Muller glia\",\n    \"description\": \"ATAC-seq data comparing chromatin accessibility in Müller glia cells overexpressing Ascl1a and lin28a versus uninjected controls in zebrafish retina.\",\n    \"dataType\": [\"chromatinActivity\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"ATAC-seq\", \"chromatin accessibility\", \"Ascl1a\", \"lin28a\", \"Müller glia\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 4,\n    \"specimenCount\": 5,\n    \"measurementTechnique\": \"ATAC-seq\",\n    \"contributor\": [\"Christina Parry\"],\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"ATACseq DAPT v DMSO\",\n    \"description\": \"ATAC-seq data comparing chromatin accessibility in zebrafish Müller glia cells treated with DAPT (a Notch signaling inhibitor) versus DMSO control.\",\n    \"dataType\": [\"chromatinActivity\", \"raw counts\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"ATAC-seq\", \"chromatin accessibility\", \"DAPT\", \"Notch inhibition\", \"Müller glia\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"measurementTechnique\": \"ATAC-seq\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"ATACseq inj v uninj\",\n    \"description\": \"ATAC-seq data comparing chromatin accessibility in Müller glia cells from injured versus uninjured zebrafish retina.\",\n    \"dataType\": [\"chromatinActivity\", \"raw counts\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"ATAC-seq\", \"chromatin accessibility\", \"injury response\", \"Müller glia\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"measurementTechnique\": \"ATAC-seq\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"Cxcl18b injury dep gene exp\",\n    \"description\": \"Quantitative PCR data measuring injury-dependent gene expression of Cxcl18b in zebrafish retina.\",\n    \"dataType\": [\"geneExpression\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"Cxcl18b\", \"chemokine\", \"injury response\", \"qPCR\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"measurementTechnique\": \"quantitative PCR\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"Cxcl18b knockdown EdU\",\n    \"description\": \"Data measuring EdU labeling in zebrafish retina with Cxcl18b knockdown to assess effects on proliferation following injury.\",\n    \"dataType\": [\"immunoassay\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"Cxcl18b\", \"chemokine\", \"EdU labeling\", \"proliferation\", \"knockdown\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"Drug screen\",\n    \"description\": \"Small molecule drug screen data testing compounds for their ability to stimulate retinal regeneration in zebrafish.\",\n    \"dataType\": [\"drugScreen\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"drug screen\", \"small molecules\", \"pharmaceutical compounds\", \"regeneration\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"Flt1 knockdown and mutant EdU injury data\",\n    \"description\": \"EdU labeling data from immunofluorescence assays measuring cell proliferation following retinal injury in Flt1 (VEGF receptor) knockdown and mutant zebrafish.\",\n    \"dataType\": [\"immunoassay\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"Flt1\", \"VEGF receptor\", \"EdU labeling\", \"proliferation\", \"knockdown\", \"mutant\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"Images NF1 knockdown\",\n    \"description\": \"Microscopy images showing effects of NF1 knockdown on zebrafish retina.\",\n    \"dataType\": [\"image\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"NF1\", \"neurofibromin\", \"knockdown\", \"morpholino\", \"microscopy\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"Myc\",\n    \"description\": \"Gene expression and cellular physiology data investigating the role of Myc family transcription factors in zebrafish retina regeneration, including qPCR data and immunofluorescence images.\",\n    \"dataType\": [\"geneExpression\", \"cellularPhysiology\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"Myc\", \"Mycb\", \"Mych\", \"transcription factors\", \"proliferation\", \"EdU\", \"TUNEL\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"measurementTechnique\": \"quantitative PCR\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"NF1 qPCR and MO knockdown\",\n    \"description\": \"Quantitative PCR data measuring NF1 expression and effects of morpholino-mediated NF1 knockdown on gene expression in zebrafish retina.\",\n    \"dataType\": [\"geneExpression\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"NF1\", \"neurofibromin\", \"knockdown\", \"morpholino\", \"qPCR\", \"Ascl1a\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"measurementTechnique\": \"quantitative PCR\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"RNAseq Ascl1a-Lin28a v control\",\n    \"description\": \"RNA sequencing data comparing gene expression in zebrafish retina with Ascl1a and Lin28a overexpression versus control.\",\n    \"dataType\": [\"geneExpression\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"RNA-seq\", \"Ascl1a\", \"Lin28a\", \"gene expression\", \"transcriptomics\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"measurementTechnique\": \"RNA-seq\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"RNAseq DAPT v DMSO MG\",\n    \"description\": \"RNA sequencing data comparing gene expression in zebrafish Müller glia cells treated with DAPT (a Notch signaling inhibitor) versus DMSO control.\",\n    \"dataType\": [\"geneExpression\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"RNA-seq\", \"DAPT\", \"Notch inhibition\", \"Müller glia\", \"gene expression\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"RNAseq inj v uninj MG\",\n    \"description\": \"RNA sequencing data comparing gene expression in Müller glia cells from injured versus uninjured zebrafish retina.\",\n    \"dataType\": [\"geneExpression\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"RNA-seq\", \"injury response\", \"Müller glia\", \"gene expression\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"RNAseq uninj v inj retina non-Muller glia\",\n    \"description\": \"RNA sequencing data comparing gene expression in non-Müller glial cells from uninjured versus injured zebrafish retina.\",\n    \"dataType\": [\"geneExpression\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"RNA-seq\", \"injury response\", \"non-Müller glia\", \"gene expression\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"Vegf signaling component gene expression\",\n    \"description\": \"Quantitative PCR data measuring expression of VEGF signaling pathway components in zebrafish retina, particularly in the context of regeneration.\",\n    \"dataType\": [\"geneExpression\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"VEGF signaling\", \"angiogenesis\", \"qPCR\", \"gene expression\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"measurementTechnique\": \"quantitative PCR\",\n    \"studyId\": \"syn21650493\"\n  },\n  {\n    \"accessType\": \"Controlled Access\",\n    \"creator\": \"Daniel Goldman\",\n    \"title\": \"scRNAseq zf retina\",\n    \"description\": \"Single-cell RNA sequencing data from zebrafish retina, providing cell-type specific gene expression profiles relevant to retinal regeneration.\",\n    \"dataType\": [\"geneExpression\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"keywords\": [\"retina regeneration\", \"single-cell RNA-seq\", \"cell types\", \"Müller glia\", \"gene expression\", \"GFP-labeled cells\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Danio rerio\"],\n    \"measurementTechnique\": \"single-cell RNA-seq\",\n    \"studyId\": \"syn21650493\"\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":8659,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":4248}}}}
{"custom_id":"syn27761862","result":{"type":"succeeded","message":{"id":"msg_018ocWC6LsGK1zf8dWr1HFVM","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the provided table based on the JSON schema and project information.\n\n```json\n[\n  {\n    \"title\": \"Proteasome-targeting drugs tested on NF2-deficient meningioma models\",\n    \"creator\": \"Vijaya Ramesh\",\n    \"alternateName\": \"NF2-deficient meningioma drug response dataset\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"NF2\",\n      \"meningioma\",\n      \"proteasome inhibitors\",\n      \"drug screen\",\n      \"cell viability\",\n      \"NF2-deficient models\"\n    ],\n    \"dataType\": [\n      \"drugScreen\"\n    ],\n    \"dataUseModifiers\": [\n      \"General Research Use\"\n    ],\n    \"description\": \"This dataset contains cell viability assay results of proteasome-targeting drugs tested on various NF2-deficient meningioma cell models and controls. The experiments include both NF2+ and NF2- cell lines using CRISPR-edited arachnoid cells (AC), Ben-Men-1, and patient-derived meningioma cells to evaluate drug response differences based on NF2 status.\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"CTF\"\n    ],\n    \"includedInDataCatalog\": \"https://www.synapse.org/DataCatalog:0\",\n    \"measurementTechnique\": \"cell viability assay\",\n    \"species\": [\n      \"Homo sapiens\",\n      \"Mus musculus\"\n    ],\n    \"studyId\": \"syn27761862\",\n    \"specimenCount\": 1,\n    \"contributor\": [\n      \"Roberta Beauchamp\",\n      \"Anh Nguyet Vu\",\n      \"Lei Xu\"\n    ],\n    \"subject\": [\n      \"Drug discovery\",\n      \"Meningioma\",\n      \"Neurofibromatosis type 2\",\n      \"Cell viability\",\n      \"Proteasome inhibitors\"\n    ],\n    \"manifestation\": [\n      \"Meningioma\"\n    ]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5812,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":562}}}}
{"custom_id":"syn11374341","result":{"type":"succeeded","message":{"id":"msg_01T8TxsTcMS2dGMcMupsEy9K","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these three tables based on the provided information.\n\n```json\n[\n  {\n    \"title\": \"Brightfield Microscopy Images of Cutaneous Neurofibromas\",\n    \"creator\": \"Roope Kallionpää\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"cutaneous neurofibroma\",\n      \"microscopy\",\n      \"CD117\",\n      \"histopathology\",\n      \"tumor microenvironment\",\n      \"mast cells\"\n    ],\n    \"dataType\": [\n      \"image\"\n    ],\n    \"studyId\": \"syn11374341\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"description\": \"This dataset contains brightfield microscopy images of cutaneous neurofibromas from NF1 patients. The images focus on CD117 staining which highlights mast cells in the tumor microenvironment, a key aspect of the study examining the role of immune cells in cutaneous neurofibroma development.\",\n    \"contributor\": [\n      \"Juha Peltonen\", \n      \"Sirkku Peltonen\"\n    ],\n    \"individualCount\": 61,\n    \"specimenCount\": 183,\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"manifestation\": [\n      \"Cutaneous Neurofibroma\"\n    ],\n    \"measurementTechnique\": \"brightfield microscopy\",\n    \"subject\": [\n      \"Tumor microenvironment\",\n      \"Mast cells\",\n      \"Neurofibromatosis Type 1\",\n      \"Cutaneous neurofibromas\"\n    ],\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ]\n  },\n  {\n    \"title\": \"T Cell Receptor Sequencing Data from Cutaneous Neurofibromas\",\n    \"creator\": \"Roope Kallionpää\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"T cell receptor\",\n      \"TCR sequencing\",\n      \"cutaneous neurofibroma\",\n      \"immune cells\",\n      \"T cells\",\n      \"tumor microenvironment\"\n    ],\n    \"dataType\": [\n      \"genomicFeatures\"\n    ],\n    \"studyId\": \"syn11374341\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"description\": \"This dataset contains T cell receptor sequencing data from cutaneous neurofibromas of NF1 patients. The data characterizes T cell populations in the tumor microenvironment, aiming to understand their role in tumorigenesis and potential as therapeutic targets.\",\n    \"contributor\": [\n      \"Juha Peltonen\", \n      \"Sirkku Peltonen\"\n    ],\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"manifestation\": [\n      \"Cutaneous Neurofibroma\"\n    ],\n    \"subject\": [\n      \"T cell receptors\",\n      \"Adaptive immunity\",\n      \"Tumor immunology\",\n      \"Neurofibromatosis Type 1\",\n      \"Cutaneous neurofibromas\"\n    ],\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ]\n  },\n  {\n    \"title\": \"Proteomic Analysis of Cutaneous Neurofibromas by Mass Spectrometry\",\n    \"creator\": \"Roope Kallionpää\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"proteomics\",\n      \"mass spectrometry\",\n      \"LC-MS/MS\",\n      \"cutaneous neurofibroma\",\n      \"skin\",\n      \"protein expression\"\n    ],\n    \"dataType\": [\n      \"proteomics\"\n    ],\n    \"studyId\": \"syn11374341\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"description\": \"This dataset contains LC-MS/MS mass spectrometry data from human cutaneous neurofibromas and overlying skin. The proteomic analysis aims to identify molecular signatures and potential therapeutic targets related to the tumor microenvironment, with a focus on immune cell components.\",\n    \"contributor\": [\n      \"Juha Peltonen\", \n      \"Sirkku Peltonen\"\n    ],\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"manifestation\": [\n      \"Cutaneous Neurofibroma\"\n    ],\n    \"measurementTechnique\": \"liquid chromatography/tandem mass spectrometry\",\n    \"subject\": [\n      \"Proteomics\",\n      \"Mass spectrometry\",\n      \"Tumor microenvironment\",\n      \"Neurofibromatosis Type 1\",\n      \"Cutaneous neurofibromas\"\n    ],\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5899,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1333}}}}
{"custom_id":"syn11374337","result":{"type":"succeeded","message":{"id":"msg_01SteffRP5AkFiNdERkwP9fn","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables based on the provided information and JSON schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Chronic Injuries Experiment in Mouse Model of Cutaneous NFs\",\n    \"creator\": \"Piotr Topilko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"chronic injuries\", \"cutaneous neurofibroma\", \"immunofluorescence\", \"mouse model\", \"NF1\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374337\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains immunofluorescence microscopy images documenting chronic injuries in a mouse model of cutaneous neurofibromas. The images provide insights into cellular responses to injury in the context of NF1.\",\n    \"species\": [\"Mus musculus\"],\n    \"individualCount\": 27,\n    \"measurementTechnique\": \"immunofluorescence\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"Development of Cutaneous Neurofibromas in Mouse Model\",\n    \"creator\": \"Piotr Topilko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibroma development\", \"NF1\", \"cutaneous neurofibroma\", \"mouse model\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374337\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset documents the developmental progression of cutaneous neurofibromas in a mouse model of NF1. The data provides insights into the initiation and progression of cNFs.\",\n    \"species\": [\"Mus musculus\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"Tumor Cell Grafts into Sciatic Nerve in Mouse Model\",\n    \"creator\": \"Piotr Topilko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"tumor cell grafts\", \"sciatic nerve\", \"neurofibroma\", \"in vivo tumor growth\", \"NF1\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374337\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains images documenting the results of grafting tumor cells into the sciatic nerve of mice to study neurofibroma development and progression in vivo.\",\n    \"species\": [\"Mus musculus\"],\n    \"individualCount\": 11,\n    \"measurementTechnique\": \"in vivo tumor growth\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"contributor\": [\"Christina Parry\"]\n  },\n  {\n    \"title\": \"Mouse Model Cutaneous Imaging of Chronic Injuries\",\n    \"creator\": \"Piotr Topilko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"chronic injuries\", \"cutaneous imaging\", \"mouse model\", \"NF1\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374337\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains imaging data from chronic injury experiments in a mouse model of cutaneous neurofibromas, providing insights into cellular responses to injury in NF1.\",\n    \"species\": [\"Mus musculus\"],\n    \"individualCount\": 27,\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"RNA-Seq Data for NF-OSI Processing\",\n    \"creator\": \"Piotr Topilko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-Seq\", \"gene expression\", \"transcriptomics\", \"NF1\", \"mouse model\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374337\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains RNA sequencing data from the mouse model of cutaneous neurofibromas, submitted for processing by NF-OSI.\",\n    \"species\": [\"Mus musculus\"]\n  },\n  {\n    \"title\": \"Bulk RNA-Seq of Sphere P0 vs P5 in Mouse Model of NF1\",\n    \"creator\": \"Piotr Topilko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-Seq\", \"bulk sequencing\", \"gene expression\", \"NF1\", \"P0\", \"P5\", \"transcriptomics\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374337\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains bulk RNA sequencing data comparing P0 and P5 spheres in the mouse model of cutaneous neurofibromas, providing insights into gene expression differences.\",\n    \"species\": [\"Mus musculus\"],\n    \"measurementTechnique\": \"RNA-seq\",\n    \"contributor\": [\"Kaitlin Throgmorton\"]\n  },\n  {\n    \"title\": \"Single-Cell Transcriptomic Analysis of Supepidermal Glia Markers\",\n    \"creator\": \"Piotr Topilko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"single-cell RNA-Seq\", \"transcriptomics\", \"supepidermal glia\", \"cell markers\", \"NF1\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374337\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains single-cell RNA sequencing data aimed at identifying new markers for supepidermal glia in the context of neurofibroma development.\",\n    \"species\": [\"Mus musculus\"],\n    \"measurementTechnique\": \"single-cell RNA-seq\"\n  },\n  {\n    \"title\": \"Vascular Detection with Itae in Mouse Model of NF1\",\n    \"creator\": \"Piotr Topilko\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"vascular detection\", \"Itae\", \"angiogenesis\", \"NF1\", \"neurofibroma\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374337\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains imaging data focusing on the detection of vascular structures in the mouse model of cutaneous neurofibromas using Itae methodology.\",\n    \"species\": [\"Mus musculus\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  }\n]\n```\n\nI've created metadata for all 8 tables based on the information provided. For each dataset, I've included:\n\n1. Descriptive titles that clearly indicate the content\n2. The creator (Piotr Topilko) who led this research\n3. Controlled Access type (appropriate for biomedical research data)\n4. Keywords relevant to each dataset's focus\n5. Appropriate data types based on the files described\n6. The study ID linking to the parent project\n7. Disease focus of Neurofibromatosis type 1\n8. NTAP as the funder\n9. Concise descriptions explaining each dataset's purpose and content\n10. Mus musculus as the species\n11. Individual counts where provided\n12. Measurement techniques where specified\n13. Manifestation of Cutaneous Neurofibroma where applicable\n14. Contributors when mentioned\n\nFor fields where specific information wasn't provided (like specimen count), I omitted those properties as instructed in the schema. The license is set to \"UNKNOWN\" as no specific license information was provided."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7045,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2092}}}}
{"custom_id":"syn11638893","result":{"type":"succeeded","message":{"id":"msg_01SUqLiFfabqkMQ3MD8Hj52y","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the 8 tables in this project, following the JSON schema provided.\n\n```json\n[\n  {\n    \"title\": \"Copy Number Variation - CNVkit\",\n    \"creator\": \"Angela C. Hirbe\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"copy number variation\", \"CNV\", \"patient-derived xenograft\", \"PDX\"],\n    \"dataType\": [\"genomicVariants\", \"CopyNumberVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Copy number variation data from NF1-MPNST patient-derived xenograft models generated using CNVkit. This dataset is part of a project developing preclinical NF1-MPNST models suitable for precision oncology drug discovery.\",\n    \"contributor\": [\"NF Service\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 10,\n    \"measurementTechnique\": \"whole genome sequencing\",\n    \"subject\": [\"Neurofibromatosis\", \"Cancer genomics\", \"Sarcoma\", \"Copy number variation\"]\n  },\n  {\n    \"title\": \"Filtered Single Cell RNASeq Data\",\n    \"creator\": \"Angela C. Hirbe\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"single-cell RNA-seq\", \"gene expression\", \"patient-derived xenograft\", \"PDX\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Filtered single-cell RNA sequencing data from NF1-MPNST specimens. This dataset provides gene expression profiles at the single-cell level to help characterize the molecular heterogeneity of MPNST tumors.\",\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"measurementTechnique\": \"single-cell RNA-seq\",\n    \"subject\": [\"Neurofibromatosis\", \"Cancer genomics\", \"Transcriptomics\", \"Single-cell analysis\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - DeepVariant Pipeline\",\n    \"creator\": \"Angela C. Hirbe\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"germline variants\", \"DeepVariant\", \"whole genome sequencing\", \"patient-derived xenograft\", \"PDX\"],\n    \"dataType\": [\"genomicVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants from NF1-MPNST samples identified using the DeepVariant pipeline. Part of a project developing preclinical NF1-MPNST models for precision oncology drug discovery.\",\n    \"contributor\": [\"NF Service\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 9,\n    \"measurementTechnique\": \"whole genome sequencing\",\n    \"subject\": [\"Neurofibromatosis\", \"Cancer genomics\", \"Germline variation\", \"Variant calling\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - FreeBayes Pipeline\",\n    \"creator\": \"Angela C. Hirbe\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"germline variants\", \"FreeBayes\", \"whole genome sequencing\", \"patient-derived xenograft\", \"PDX\"],\n    \"dataType\": [\"genomicVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants from NF1-MPNST samples identified using the FreeBayes variant calling pipeline. This dataset contributes to the molecular characterization of MPNST heterogeneity.\",\n    \"contributor\": [\"NF Service\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 9,\n    \"measurementTechnique\": \"whole genome sequencing\",\n    \"subject\": [\"Neurofibromatosis\", \"Cancer genomics\", \"Germline variation\", \"Variant calling\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - Mutect2 Pipeline\",\n    \"creator\": \"Angela C. Hirbe\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"germline variants\", \"Mutect2\", \"whole genome sequencing\", \"patient-derived xenograft\", \"PDX\"],\n    \"dataType\": [\"genomicVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants from NF1-MPNST samples identified using the Mutect2 variant calling pipeline. This dataset is part of a comprehensive approach to characterize the genetic heterogeneity in MPNSTs.\",\n    \"contributor\": [\"NF Service\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 9,\n    \"measurementTechnique\": \"whole genome sequencing\",\n    \"subject\": [\"Neurofibromatosis\", \"Cancer genomics\", \"Germline variation\", \"Variant calling\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - Strelka Pipeline\",\n    \"creator\": \"Angela C. Hirbe\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"germline variants\", \"Strelka\", \"whole genome sequencing\", \"patient-derived xenograft\", \"PDX\"],\n    \"dataType\": [\"genomicVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants from NF1-MPNST samples identified using the Strelka variant calling pipeline. Part of an effort to develop and characterize PDX models representing the molecular heterogeneity of MPNSTs.\",\n    \"contributor\": [\"NF Service\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 9,\n    \"measurementTechnique\": \"whole genome sequencing\",\n    \"subject\": [\"Neurofibromatosis\", \"Cancer genomics\", \"Germline variation\", \"Variant calling\"]\n  },\n  {\n    \"title\": \"NFOSI-WES-To-Process-2024-09\",\n    \"creator\": \"Angela C. Hirbe\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"whole exome sequencing\", \"WES\", \"patient-derived xenograft\", \"PDX\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Whole exome sequencing data from NF1-MPNST patient-derived xenograft models. This dataset contains raw sequencing files (FASTQ) awaiting processing to support the development of preclinical models for precision oncology.\",\n    \"contributor\": [\"Chang In Moon\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus (humanized)\"],\n    \"individualCount\": 6,\n    \"specimenCount\": 13,\n    \"measurementTechnique\": \"whole exome sequencing\",\n    \"subject\": [\"Neurofibromatosis\", \"Cancer genomics\", \"Exome sequencing\", \"Sarcoma\"]\n  },\n  {\n    \"title\": \"NFOSIprocessing-2022-26-04\",\n    \"creator\": \"Angela C. Hirbe\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"whole genome sequencing\", \"WGS\", \"patient-derived xenograft\", \"PDX\", \"BAM files\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Processed whole genome sequencing data (BAM files) from NF1-MPNST patient-derived xenograft models. This dataset includes both tumor and matched normal samples to facilitate the identification of somatic variants.\",\n    \"contributor\": [\"Chang In Moon\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus (humanized)\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 11,\n    \"measurementTechnique\": \"whole genome sequencing\",\n    \"subject\": [\"Neurofibromatosis\", \"Cancer genomics\", \"Whole genome sequencing\", \"Sarcoma\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":8511,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2695}}}}
{"custom_id":"syn23662493","result":{"type":"succeeded","message":{"id":"msg_019VRyuWr2UpJVNCU3gsbS9V","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata Curation\n\nBased on the provided information, I've created metadata for each table in the project:\n\n```json\n[\n  {\n    \"title\": \"Affinity Purified ELISA Screen\",\n    \"creator\": \"Michelle Mattson-Hoss\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibromin\", \"NF1\", \"antibody\", \"ELISA\", \"affinity purification\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"ELISA screening data for affinity-purified antibodies against neurofibromin. Part of efforts to develop an improved monoclonal antibody against NF1 with enhanced sensitivity and specificity.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"ELISA\",\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Epitope Mapping\",\n    \"creator\": \"Michelle Mattson-Hoss\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibromin\", \"NF1\", \"antibody\", \"epitope mapping\", \"western blot\"],\n    \"dataType\": [\"immunoassay\", \"image\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Western blot data for epitope mapping of neurofibromin antibodies. This dataset helps identify specific binding regions of developed antibodies on the neurofibromin protein.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"western blot\",\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"IHC Data\",\n    \"creator\": \"Michelle Mattson-Hoss\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibromin\", \"NF1\", \"antibody\", \"immunohistochemistry\", \"tissue staining\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Immunohistochemistry images showing the performance of neurofibromin antibodies in various human tissues including adrenal, cerebellar cortex, and cerebral cortex regions.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"immunohistochemistry\",\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Sandwich ELISA\",\n    \"creator\": \"Michelle Mattson-Hoss\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibromin\", \"NF1\", \"antibody\", \"sandwich ELISA\", \"protein quantification\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Sandwich ELISA data demonstrating the utility of developed neurofibromin antibodies in a more complex immunoassay format, allowing for sensitive protein quantification.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"ELISA\",\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Sequence Data\",\n    \"creator\": \"Michelle Mattson-Hoss\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibromin\", \"NF1\", \"antibody\", \"protein sequencing\", \"mass spectrometry\", \"NGS\"],\n    \"dataType\": [\"proteomics\", \"geneExpression\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Mass spectrometry and next-generation sequencing data related to antibody development against neurofibromin. Includes proteomics data derived from rabbit specimens.\",\n    \"species\": [\"Oryctolagus cuniculus\"],\n    \"individualCount\": 1,\n    \"measurementTechnique\": \"liquid chromatography/tandem mass spectrometry\",\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Titer Report\",\n    \"creator\": \"Michelle Mattson-Hoss\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibromin\", \"NF1\", \"antibody\", \"titer\", \"ELISA\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Antibody titer reports from ELISA assays, providing information on the concentration and activity of developed neurofibromin antibodies.\",\n    \"measurementTechnique\": \"ELISA\",\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Western Blot Screening\",\n    \"creator\": \"Michelle Mattson-Hoss\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibromin\", \"NF1\", \"antibody\", \"western blot\", \"protein detection\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Western blot screening images showing antibody binding to neurofibromin in various samples. Includes results from multiple antibody clones (05D, 06G, 07E, 08D, 10D).\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": \"western blot\",\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  }\n]\n```\n\nThese metadata entries contain the required fields and relevant optional fields based on the available information. Each entry reflects the specific nature of the dataset while maintaining consistency with the project's overall focus on developing improved monoclonal antibodies against neurofibromin for NF1 research."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6600,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1700}}}}
{"custom_id":"syn4939888","result":{"type":"succeeded","message":{"id":"msg_01XVvdjQ2QhfwXprxtofAicc","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata\n\n```json\n[\n  {\n    \"title\": \"Patient Reported Outcomes for NF1-Associated Plexiform Neurofibromas\",\n    \"creator\": \"Jin-Shei Lai\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"Patient Reported Outcomes\", \n      \"PRO\", \n      \"quality of life\", \n      \"pain\", \n      \"stigma\", \n      \"organ dysfunction\", \n      \"plexiform neurofibroma\", \n      \"survey\"\n    ],\n    \"dataType\": [\n      \"surveyData\",\n      \"clinical\"\n    ],\n    \"studyId\": \"syn4939888\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"description\": \"This dataset contains patient reported outcomes (PRO) data collected from NF1 patients with plexiform neurofibromas. It includes both pediatric and adult responses to questionnaires assessing health-related quality of life, pain, stigma, and organ dysfunction. The data was collected to develop and validate a PRO measurement system specifically for patients with plexiform neurofibromas for use in clinical trials.\",\n    \"contributor\": [\n      \"Jin-Shei Lai\", \n      \"Sara Gosline\"\n    ],\n    \"manifestation\": [\n      \"Plexiform Neurofibroma\", \n      \"Pain\", \n      \"Quality of Life\"\n    ],\n    \"measurementTechnique\": \"questionnaire\",\n    \"subject\": [\n      \"Patient reported outcome measures\", \n      \"Quality of life\", \n      \"Neurofibromatosis type 1\", \n      \"Clinical trials\"\n    ],\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\",\n      \"General Research Use\"\n    ]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5799,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":504}}}}